Literature DB >> 29122427

Transcanal endoscopic ear surgery for perilymphatic fistula after electric acoustic stimulation.

Ryotaro Omichi1, Shin Kariya2, Yukihide Maeda1, Kazunori Nishizaki1.   

Abstract

Transcanal endoscopic ear surgery (TEES) will become a very useful therapeutic option. A perilymphatic fistula (PLF) is defined as sudden sensorineural hearing loss and/or vertigo caused by leakage of the perilymph through a fistula from the oval window and/or round window. We report a case of PLF after electric acoustic stimulation (EAS), a kind of cochlear implant, successfully treated by TEES. A 38-year-old man presented to our hospital with vertigo and hearing loss (HL). His vertigo was induced by Valsalva maneuvers. Eight months ago, he underwent EAS for his right ear for congenital sensorineural HL. Although he maintained his hearing level after EAS, his pure tone audiogram this time showed deterioration of hearing at low frequencies in his right ear. A diagnosis of right PLF was made. After confirming the non-effectiveness of oral prednisolone treatment, PLF repair surgery to patch the oval and round windows by TEES was performed. His vertigo did not recur after the surgery. To the best of our knowledge, this is the first report of PLF repair surgery by TEES without a microscope. The wide-field view of the middle ear by TEES was useful to prevent electrode damage in a PLF patient with a cochlear implant.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cochlear implantation; Electric acoustic stimulation; Hearing loss; Perilymphatic fistula; Transcanal endoscopic ear surgery; Vertigo

Mesh:

Year:  2017        PMID: 29122427     DOI: 10.1016/j.anl.2017.10.004

Source DB:  PubMed          Journal:  Auris Nasus Larynx        ISSN: 0385-8146            Impact factor:   1.863


  1 in total

1.  Endoscopic Repair of Traumatic Perilymphatic Fistula in Children: A Case Series.

Authors:  Rounak Rawal; Xue Zhao; Sophie Lipson; Jacob R Brodsky
Journal:  J Int Adv Otol       Date:  2021-03       Impact factor: 1.316

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.